ClinicalTrials.gg

Program

Actinium Ac 225 RTX-2358

Its studies are mostly in Sarcoma, led by Ratio Therapeutics.

Furthest: phase 1, since Jan 17, 20251 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ratio Therapeutics11 open or runningphase 1since Jan 17, 2025Jan 17, 2025Jan 2028phase 1 · NCT07156565

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 17, 2025First study: phase 1 study in SarcomaFirst studyNCT07156565 · 48 enrolled · United States, Canada

Ahead

  1. Jan 2028Primary completion: phase 1 study in SarcomaNCT07156565

TargetBeta

FAP →read by rule
“A radioconjugate composed of a fibroblast activation protein (FAP)-targeting moiety, ”NCIt, by rule

Other programs on FAP

ProgramCompanyFurthest phaseStudies
Lutetium-177Novartisphase 324
Gallium-68Philogenphase 317
Fluorine F 18 FAPI-74rulesofiephase 33
Fluorine F 18 FPyQCPruleBraccophase 21
HRS-6768Jiangsu HengRui Medicinephase 21
Anti-FAP Antibody-drug Conjugate OMTX705ruleoncomatryx-biopharma-s-lphase 12
Gallium Ga 68 NNS309Novartisphase 12
Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713ruleEli Lillyphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050ruleImmunomephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07156565Sarcoma · United States, Canada1Active, not recruitingJan 202848

How it is read

Names in the registry

  • “[Ac 225]RTX-2358”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.